Criteria to interpret cancer biomarker increments crossing the recommended cut-off compared in a simulation model focusing on false positive signals and tumour detection time

Clinica Chimica Acta

Volumn 431, Issue , 2014, Pages 192-197

  Lund, Flemming ^a   Petersen, Per Hyltoft ^a,b   Pedersen, Merete Frejstrup ^a   Hassan, Suher Othman Abu ^a   Sölétormos, György ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

Baseline concentration; Biological variation; False positive results; Monitoring; True positive results; Tumour detection time

Indexed keywords

TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; COMPARATIVE STUDY; COMPUTER SIMULATION; CONCENTRATION (PARAMETERS); CRITERION RELATED VALIDITY; FALSE POSITIVE RESULT; HUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; STEADY STATE; TUMOR DETECTION TIME; TUMOR GROWTH; ALGORITHM; DISEASE COURSE; LABORATORY DIAGNOSIS; NEOPLASMS; PATHOLOGY; REFERENCE VALUE;

ALGORITHMS; COMPUTER SIMULATION; DISEASE PROGRESSION; FALSE POSITIVE REACTIONS; HUMANS; NEOPLASMS; REFERENCE VALUES; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84894645844     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.01.013     Document Type: Article

References (16)

1. Sölétormos G., Nielsen D., Schiøler V., Skovsgaard T., Dombernowsky P. Tumour markers cancer antigen 15.3, and tissue polypeptide antigen for monitoring metastatic breast cancer during first-line chemotherapy and follow-up. Clin Chem 1996, 42:564-575.
2. Nicolini A., Tartarelli G., Carpi A., et al. Intensive post-operative follw-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases. BMC Cancer 2006, 6:269.
3. Sölétormos G., Schiøler V., Nielsen D., Skovsgaard T., Dombernowsky P. Interpretation of results for tumour markers on the basis of analytical imprecision and biological variation. Clin Chem 1993, 39:2077-2083.
4. Sölétormos G., Petersen P.H., Dombernowsky P. Assessment of CA 15.3, CEA and TPA concentrations during monitoring of breast cancer. Clin Chem Lab Med 2000, 38:453-463.
5. Sölétormos G., Hyltoft Petersen P., Dombernowsky P. Progresssion criteria for cancer antigen 15.3 and carcinoembryonic antigen in metastatic breast cancer compared by computer simulation of marker data. Clin Chem 2000, 46:939-949.
6. Sölétormos G., Petersen P.H., Nielsen D. Computer-simulated tumour-marker data used to compare progression criteria for cytokeratin tissue polypeptide antigen in metastatic breast cancer. Clin Chem 2001, 47:2035-2037.
7. Petersen P.H., Sölétormos G., Pedersen M.F., Lund F. Interpretation of increments in serial tumour biomarker concentrations depends on the distance of the baseline concentration from the cut-off. Clin Chem Lab Med 2011, 49:303-310.
8. Lund F., Sölétormos G., Pedersen M.F., Petersen P.H. Computer simulation model system for interpretation and validation of algorithms for monitoring of cancer patients by use of serial serum concentrations of biomarkers in the follow-up after surgical procedures and other treatments. Biomarker 2012, 295-318. InTech, Rijeka. T.K. Khan (Ed.).
9. Fraser C.G. Biological Variation: From Principles to Practice 2001, AACC Press, Washington, DC.
10. Bliss C.I. Statistics in biology 1967, McGraw-Hill Book Company, New York.
11. Barak M., Steiner M., Finkel B., Abrahamson J., Antal S., Gruener N. CA-15.3, TPA and MCA as markers for breast cancer. Eur J Cancer 1990, 26:577-580.
12. Tondini C., Hayes D.F., Gelman R., Craig Henderson I., Kufe D. Comparison of CA 15-3 and carcinoembryonic antigen in monitoring the critical course of patients with metastatic breast cancer. Cancer Res 1988, 48:4107-4112.
13. Chan D.W., Beveridge R.A., Muss H., et al. Use of Truquantt BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disesase. J Clin Oncol 1997, 15:2322-2328.
14. Molina R., Zanón G., Filella X., et al. Use of serial carcinoembryonic antigen and CA 15-3 assays in detecting relapses in breast cancer patients. Breast Cancer Res Treat 1995, 36:41-48.
15. [accessed 3.12.2013]. http://en.wikipedia.org/wiki/Linear_interpolation.
16. Sölétormos G., Duffy M.J., Hayes D.F., et al. Design of tumor biomarker-monitoring trials: a proposal by the European Group on Tumor Markers. Clin Chem 2013, 59:52-59.